1352-Menin Inhibition Targets Pathogenic Megakaryopoiesis
This paper details research into menin inhibition as a novel therapeutic strategy for myeloproliferative neoplasms (MPNs), a group of blood cancers characterized by excessive cell production and bone marrow fibrosis. Researchers discovered that the menin-KMT2A interaction is essential for the survival and maturation of megakaryocyte progenitors, which are the primary drivers of disease progression in conditions like myelofibrosis. Utilizing the inhibitor revumenib, the study demonstrates a significant reduction in pathogenic megakaryocytes and a successful reversal of bone marrow scarring in…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.